BD Completes GeneOhm buy
This article was originally published in The Gray Sheet
Executive Summary
BD will launch a global initiative to reduce healthcare-associated infections after completing its acquisition of molecular diagnostic firm GeneOhm Sciences (1"The Gray Sheet" Jan. 16, 2006, p. 5). BD announced Jan. 10 that it would pay $230 mil., plus up to $25 mil. in milestone payments, to acquire the firm. Assays currently available from GeneOhm include the IDI-Strep B assay for detecting Group B Strep, and IDI-MRSA for detecting methicillin-resistant Staphylococcus aureus. BD has speculated that the market could be worth more than $500 mil...